Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Van Der Lely, Aart Jan, et al. Long-term Treatment of Acromegaly with Pegvisomant, a Growth Hormone Receptor Antagonist. 2001. https://doi.org/10.17615/82mk-gm08APA
Van Der Lely, A., Hutson, R., Trainer, P., Besser, G., Barkan, A., Katznelson, L., Klibanski, A., Herman Bonert, V., Melmed, S., Vance, M., Freda, P., Stewart, P., Friend, K., Clemmons, D., Johannsson, G., Stavrou, S., Cook, D., Phillips, L., Strasburger, C., Hackett, S., Zib, K., Davis, R., Scarlett, J., & Thorner, M. (2001). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. https://doi.org/10.17615/82mk-gm08Chicago
Van Der Lely, Aart Jan, R. Kent Hutson, Peter J Trainer, G. Michael Besser, Ariel L Barkan, Laurence Katznelson, Anne Klibanski et al. 2001. Long-Term Treatment of Acromegaly with Pegvisomant, a Growth Hormone Receptor Antagonist. https://doi.org/10.17615/82mk-gm08- Creator
-
van der Lely, Aart Jan
- Other Affiliation: Erasmus Medical Centre Rotterdam, 40 Dr Molewaterplein, 3015 GD Rotterdam, Netherlands
-
Hutson, R. Kent
- Other Affiliation: University of Tennessee, Knoxville, TN, USA
-
Trainer, Peter J.
- Other Affiliation: Christie Hospital, Manchester, UK
-
Besser, G. Michael
- Other Affiliation: St Bartholomew’s Hospital, London, UK
-
Barkan, Ariel L.
- Other Affiliation: University of Michigan Medical Center, Ann Arbor, MI, USA
-
Katznelson, Laurence
- Other Affiliation: Massachusetts General Hospital, Boston, MD, USA
-
Klibanski, Anne
- Other Affiliation: Massachusetts General Hospital, Boston, MD, USA
-
Herman-Bonert, Vivien
- Other Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA, USA
-
Melmed, Shlomo
- Other Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA, USA
-
Vance, Mary Lee
- Other Affiliation: University of Virginia Health Sciences Center, Charlottesville, VA, USA
-
Freda, Pamela U.
- Other Affiliation: Columbia College of Physicians and Surgeons, New York, NY, USA
-
Stewart, Paul M.
- Other Affiliation: Queen Elizabeth Hospital, Birmingham, UK
-
Friend, Keith E.
- Other Affiliation: University of Texas M D Anderson Cancer Center, Houston, TX, USA
-
Clemmons, David
- Affiliation: School of Medicine, Department of Medicine, Division of Endocrinology and Metabolism
-
Johannsson, Gudmundur
- Other Affiliation: Såhlgrenska University Hospital, Goteborg, Sweden
-
Stavrou, Stavros
- Other Affiliation: New York University Medical Center, New York, NY, USA
-
Cook, David M.
- Other Affiliation: Oregon Health Sciences University, Portland, OR, USA
-
Phillips, Lawrence S.
- Other Affiliation: Emory University School of Medicine, Atlanta, GA, USA
-
Strasburger, Christian J.
- Other Affiliation: Klinikum Innenstadt, Ludwig-Maximilians-Universität, Munich, Germany
-
Hackett, Suzanne
- Other Affiliation: StatWorks Inc, Chapel Hill, NC, USA
-
Zib, Kenneth A.
- Other Affiliation: Sensus Drug Development Corporation, Austin, TX, USA
-
Davis, Robert J.
- Other Affiliation: Sensus Drug Development Corporation, Austin, TX, USA
-
Scarlett, John A.
- Other Affiliation: Sensus Drug Development Corporation, Austin, TX, USA
-
Thorner, Michael O.
- Other Affiliation: University of Virginia Health Sciences Center, Charlottesville, VA, USA
- Abstract
- "Background Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. Findings Mean serum IGF-1 concentrations fell by at least 50%: 467 μg/L (SE 24), 526 μg/L (29), and 523 μg/L (40) in patients treated for 6, 12 and 18 months, respectively (p less than 0·001), whereas growth hormone increased by 12·5 μg/L (2·1), 12·5 μg/L (3·0), and 14·2 μg/L (5·7) (p less than 0·001). Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. In patients withdrawn from pegvisomant (n=45), serum growth hormone concentrations were 8·0 μg/L (2·5) at baseline, rose to 15·2 μg/L (2·4) on drug, and fell back within 30 days of withdrawal to 8·3 μg/L (2·7). Antibodies to growth hormone were detected in 27 (16·9%) of patients, but no tachyphylaxis was seen. Serum insulin and glucose concentrations were significantly decreased (p less than 0·05). Two patients experienced progressive growth of their pituitary tumours, and two other patients had increased alanine and asparate aminotransferase concentrations requiring withdrawal from treatment. Mean pituitary tumour volume in 131 patients followed for a mean of 11·46 months (0·70) decreased by 0·033 cm3(0·057; p=0·353). Interpretation Pegvisomant is an effective medical treatment for acromegaly."
- Date of publication
- 2001
- DOI
- Identifier
- 2-s2.0-0035944825
- https://doi.org/10.1016/S0140-6736(01)06844-1
- Related resource URL
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- Lancet
- Journal volume
- 358
- Journal issue
- 9295
- Page start
- 1754
- Page end
- 1759
- Language
- English
- Version
- Postprint
- ISSN
- 0140-6736
Relations
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
Long-term treatment of acromegaly with pegvisomant.pdf | 2019-05-03 | Public | Download |